Novel Antithrombotic and Fibrinolytic Agents for ACSDr. Robert Giugliano's areas of research interests include novel antithrombotic and fibrinolytic agents for acute coronary syndromes (ACS), lipid-lowering therapies, and the assessment of outcomes in patients with ACS. He has authored over 100 articles, 25 editorials/book chapters, and given over 150 lectures nationally and internationally.
Dr. Giugliano has served as the lead investigator and physician-in-charge of six multicenter phase-II or III trials (TIMI 15A, TIMI 15B, INTEGRITI-TIMI 20, ADVANCE MI-TIMI 29, ANTHEM-TIMI 32, EARLY-ACS TIMI 39). In addition, he has worked closely with Dr. Elliott Antman and Dr. Christopher Cannon coordinating another six international trials, and continues to serve as the local investigator as a participating hospital for four additional studies. He is a co-investigator of five international thrombolytic studies working with Drs. Antman (TIMI 14, InTIME-II, and InTIME-IIb) and Cannon (TIMI 10B, ASSENT I) and one international trial with Dr Cannon in lipid-lowering therapies (IMPROVE-IT).
Outside of TIMI, he continues to collaborate with independent research groups (Massachusetts General Hospital, Montreal Heart Institute) studying clinical practice guidelines and risk stratification in unstable angina.
www.timi.org
References:
Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000;140(1):81-93.
Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM, Combination reperfusion therapy with epifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003;41(8):1251-60.
Giugliano RP, Newby LK, Harrington RA, Gibson CM, Vande Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E, The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute syndrome--study design and rationale. Am Heart J. 2005;149(6):994-1002.
Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Lessar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E. Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) in Patiens with non-ST-Elevation Acute Coronary Syndrome - The ANTHEM (Anticoagulation with rNAPc@ To Help Eliminate MACE) - TIMI 32 Trial. J am Coll Cardiol. 2007:49.
Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol.2006; 48(2):386-95.
Send Feedback to: 
